Healthcare provider profile · identity verified

Leonor Forero, MD

Family Practice · EASTON, PA · NPI 1043202161

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	485	129
Amlodipine Besylate	Amlodipine Besylate	290	73
Levothyroxine Sodium	Levothyroxine Sodium	236	61
Rosuvastatin Calcium	Rosuvastatin Calcium	236	66
Losartan Potassium	Losartan Potassium	232	57
Omeprazole	Omeprazole	226	53
Lisinopril	Lisinopril	220	61
Metformin Hcl	Metformin Hcl	191	52
Gabapentin	Gabapentin	164	43
Metoprolol Succinate	Metoprolol Succinate	160	40
Simvastatin	Simvastatin	146	40
Valsartan	Valsartan	142	37
Albuterol Sulfate Hfa	Albuterol Sulfate	140	38
Escitalopram Oxalate	Escitalopram Oxalate	134	33
Famotidine	Famotidine	120	32
Alprazolam	Alprazolam	113	35
Carvedilol	Carvedilol	109	23
Hydrochlorothiazide	Hydrochlorothiazide	104	27
Pantoprazole Sodium	Pantoprazole Sodium	104	35
Glimepiride	Glimepiride	102	22
Zolpidem Tartrate	Zolpidem Tartrate	100	19
Pravastatin Sodium	Pravastatin Sodium	94	24
Metformin Hcl Er	Metformin Hcl	93	31
Citalopram Hbr	Citalopram Hydrobromide	90	21
Bupropion Xl	Bupropion Hcl	84	27
Meloxicam	Meloxicam	75	22
Alendronate Sodium	Alendronate Sodium	74	16
Metoprolol Tartrate	Metoprolol Tartrate	72	23
Eliquis	Apixaban	69	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	66	13
Tamsulosin Hcl	Tamsulosin Hcl	64	19
Furosemide	Furosemide	63	21
Ezetimibe	Ezetimibe	61	19
Sertraline Hcl	Sertraline Hcl	59	16
Duloxetine Hcl	Duloxetine Hcl	58	13
Montelukast Sodium	Montelukast Sodium	57	14
Potassium Chloride	Potassium Chloride	57	16
Mounjaro	Tirzepatide	53	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	52	12
Lorazepam	Lorazepam	48	12
Ozempic	Semaglutide	48	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	46	suppressed
Allopurinol	Allopurinol	45	13
Tramadol Hcl	Tramadol Hcl	44	12
Azithromycin	Azithromycin	42	37
Clopidogrel	Clopidogrel Bisulfate	42	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	15
Januvia	Sitagliptin Phosphate	39	suppressed
Jardiance	Empagliflozin	39	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	12
Atenolol	Atenolol	38	11
Oxybutynin Chloride Er	Oxybutynin Chloride	37	11
Celecoxib	Celecoxib	36	11
Fluticasone Propionate	Fluticasone Propionate	35	12
Propranolol Hcl Er	Propranolol Hcl	34	suppressed
Nystatin	Nystatin	32	13
Synthroid	Levothyroxine Sodium	30	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	27	suppressed
Amoxicillin	Amoxicillin	25	19
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	18
Buspirone Hcl	Buspirone Hcl	24	suppressed
Fenofibrate	Fenofibrate	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Naproxen	Naproxen	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Clonazepam	Clonazepam	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
True Comfort Safety Pen Needle	Pen Needle, Diabetic, Safety	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Glipizide Er	Glipizide	19	suppressed
Lansoprazole	Lansoprazole	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	12
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Carvedilol Er	Carvedilol Phosphate	16	suppressed
Finasteride	Finasteride	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Single Use Swab	Alcohol Antiseptic Pads	15	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Ramipril	Ramipril	14	suppressed
Rexulti	Brexpiprazole	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Glipizide	Glipizide	13	suppressed
Mometasone Furoate	Mometasone Furoate	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Trazodone Hcl	Trazodone Hcl	13	suppressed
Varenicline Tartrate	Varenicline Tartrate	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error